^
Association details:
| Biomarker: | CAV1 overexpression + CAV2 overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Published date:
07/11/2023
Excerpt:
We correlated tumor CAV1/2 RNA expression with pathologic complete response (pCR), disease-free survival (DFS) and overall survival (OS) in the GeparSepto trial, which randomized patients to neoadjuvant paclitaxel- versus nab-paclitaxel-based chemotherapy....Patients treated with nab-paclitaxel with high CAV1/2 had higher probability of obtaining a pCR (CAV1 odds ratio (OR) = 4.92, 95% CI 1.70-14.22, p=0.003; CAV2 OR=5.39, 95%CI 1.76-16.47, p=0.003) as compared to patients with high CAV1/2 treated with solvent-based paclitaxel (CAV1 OR=0.33, 95%CI 0.11-0.95, p=0.040; CAV2 OR=0.37, 95%CI 0.12-1.13, p=0.082)....in nab-paclitaxel-treated patients, high CAV1/2 expression is associated with increased pCR...
DOI:
10.1158/1078-0432.CCR-23-0362
